Dexamethasone

Concomitant use may lead to hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Concomitant use with potassium-depleting agents increases risk of hypokalemia and cardiac complications including cardiac enlargement and congestive heart failure.

Concomitant use may produce severe weakness in patients with myasthenia gravis.

Strong CYP3A4/5 inducer reduces axitinib plasma exposure. Co-administration should be avoided.

May increase the clearance of dexamethasone and potentially decrease corticosteroid exposure. Avoid coadministration and consider alternative agents.

Increased activity of both cyclosporine and dexamethasone may occur; convulsions have been reported with concurrent use.

Coadministration may decrease dexamethasone exposure, which may result in loss of efficacy. Avoid concomitant use or consider increasing the dose of dexamethasone.

Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia induced by dexamethasone.

Increased dexamethasone exposure. Reduce oral dexamethasone dose by approximately 50%.

Ketoconazole, a strong CYP 3A4 inhibitor, may decrease metabolism of corticosteroids by up to 60%, leading to increased plasma concentrations.

Increases metabolism of contraceptive steroids, reducing contraceptive effectiveness and potentially resulting in unintended pregnancy or unscheduled bleeding.

Coadministration increases dexamethasone exposure, which may increase the risk of adverse reactions. Avoid concomitant use or closely monitor for adverse drug reactions.

Dexamethasone may reduce the response to anticoagulants. Frequently monitor coagulation indices to maintain the desired anticoagulant effect.

May decrease hepatic metabolism of dexamethasone and increase exposures, which may increase the risk of adverse reactions.

Pegaspargase may increase the risk of glucocorticoid-induced toxicities, including osteonecrosis through a potential increase in exposure of dexamethasone.

Strong CYP3A4 inducer that decreases toremifene steady-state concentration and should be avoided.

Dexamethasone may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents.

Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when dexamethasone was coadministered with albendazole.

Aminoglutethimide may diminish adrenal suppression by dexamethasone.

Increased dexamethasone exposure. Reduce oral dose by approximately 50%.

CYP 3A4 inducers may enhance metabolism of dexamethasone, requiring dosage increase.

CYP 3A4 inducers may enhance metabolism of dexamethasone, requiring dosage increase.

Dexamethasone is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased caspofungin dosing should be considered.

Coadministration with dabrafenib can result in decreased concentrations and loss of efficacy. Substitute or monitor for loss of efficacy if unavoidable.

CYP3A4 inducer that increases diazepam elimination, potentially decreasing efficacy.

Ephedrine may enhance metabolic clearance of dexamethasone, resulting in decreased blood levels and requiring dosage increase.

CYP 3A4 Inhibitors: Concomitant administration of dexamethasone with erythromycin, a moderate CYP 3A4 inhibitor, has the potential to result in increased plasma concentrations of dexamethasone. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration.

Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.

Increased dexamethasone exposure. Reduce dose of oral dexamethasone by approximately 50%.

False-negative results in dexamethasone suppression test have been reported in patients treated with indomethacin.

Serum concentrations of isoniazid may be decreased by dexamethasone.

May cause significant decrease in dexamethasone clearance.

Dexamethasone induces CYP3A4, potentially increasing the rate of elimination of donepezil.

CYP3A4 inducer that may lower mifepristone serum concentrations and reduce efficacy. Verify treatment success through follow-up assessment.

Netupitant increases systemic exposure of dexamethasone more than 2-fold on Days 2 and 4; administer reduced dose of dexamethasone with AKYNZEO.

CYP 3A4 inducers may enhance metabolism of dexamethasone, requiring dosage increase.

Corticosteroids may cause sodium retention with resultant edema and potassium loss when used with potassium-depleting agents. Closely monitor potassium levels.

CYP 3A4 inducers may enhance metabolism of dexamethasone, requiring dosage increase.

Thalidomide Toxic epidermal necrolysis has been reported with concomitant use of thalidomide. Closely monitor for toxicity when thalidomide is coadministered with HEMADY.

Dexamethasone usually inhibits response to warfarin; coagulation indices should be monitored frequently.

No clinically significant drug interactions observed when coadministered with bortezomib.

Co-administration with other drugs which strongly inhibit CYP 3A4 (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased plasma concentrations of corticosteroids and potentially increase the risk for systemic corticosteroid side effects.

Important drug interactions involving dexamethasone with elotuzumab; refer to dexamethasone prescribing information for details.

Co-adminstration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration.

Co-administration with other drugs which strongly inhibit CYP 3A4 (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased plasma concentrations of corticosteroids and potentially increase the risk for systemic corticosteroid side effects.

Co-administration with other drugs which strongly inhibit CYP 3A4 (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased plasma concentrations of corticosteroids and potentially increase the risk for systemic corticosteroid side effects.